IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Immutep Ltd. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased Immutep securities may be entitled to compensation through a class action without any out-of-pocket fees, as the Rosen Law Firm prepares to seek recovery of investor losses [2]. - Interested investors can join the prospective class action by submitting a form or contacting the firm directly [2]. Group 2: Company News and Stock Impact - On March 13, 2026, Immutep announced the discontinuation of the TACTI-004 Phase III study for eftilagimod alfa in non-small cell lung cancer, following a recommendation from the Independent Data Monitoring Committee based on a futility analysis [3]. - Following this announcement, Immutep's American Depositary Receipt (ADR) price fell by $2.28, or 82.6%, closing at $0.48 per ADR on the same day [3]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4].